주식/증권
📈 긍정적
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
요약
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.